Yangtze Life Sciences (00775): Shunpu Pharmaceutical Technology to Present Latest Preclinical Data for Two Cancer Vaccines at SITC 2026 Annual Meeting

Zhitong Finance APP News, CK Life Sciences (00775) announces that its wholly-owned subsidiary Sequencio Therapeutics Company Limited ("Sequencio Therapeutics") will present the latest research data from its leading cancer vaccine projects, namely the TROP2 circRNA-LNP vaccine and the PD-L1/PRAME dual-antigen vaccine, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting to be held in Phoenix, Arizona, USA.